Trials that use: Log-rank test
New to this method? Read the tutorial →
412 results
- PROCLAIMIndependent statistical analysis of the PROCLAIM phase 3 trial, including its randomized design, overall survival analysis, progression-free survival, response, relapse patterns, swallowing outcomes, safety, statistical methods, and interpretation.
- PROFILE 1014Independent statistical analysis of PROFILE 1014, evaluating crizotinib versus pemetrexed plus cisplatin or carboplatin in ALK-positive non-squamous lung cancer, with detailed interpretation of progression-free survival, overall survival, response, patient-reported outcomes, and statistical…
- ProspectIndependent statistical analysis of A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer: primary endpoint results, effect estimate with…
- PROTECTIndependent statistical analysis of the randomized phase 3 PROTECT trial of sipuleucel-T in prostate cancer, including its time-to-biochemical-failure endpoints, stratified log-rank analysis, hazard ratio, confidence interval, and statistical interpretation.
- RA-BRANCHIndependent statistical analysis of A Study of Baricitinib in Participants With Rheumatoid Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04086745).
- RADIANTA detailed statistical analysis and educational interpretation of the RADIANT phase 3 trial of erlotinib versus placebo after surgery in EGFR-positive non-small cell lung cancer, focusing on disease-free survival and time-to-event methodology.
- REACTComplete statistical analysis of the REACT phase 3 trial of two years of adjuvant celecoxib versus placebo in primary breast cancer, including trial design, disease-free survival, overall survival, statistical methodology, and interpretation.
- READYComplete statistical analysis of the READY phase 3 trial of docetaxel plus dasatinib versus docetaxel plus placebo in castration-resistant prostate cancer, including trial design, overall survival, secondary endpoints, statistical methodology, safety, and…
- RECIAIndependent statistical analysis of Multifactorial Approach to Emergent Cerclage: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01114516).
- RECORD-4Independent statistical analysis of Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01491672).
- REFLEXIONIndependent statistical analysis of Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00813709).
- RELATIVITY-047Independent statistical analysis of RELATIVITY-047, evaluating relatlimab plus nivolumab versus nivolumab alone in participants with advanced melanoma, including trial design, progression-free survival, statistical methodology, interpretation, and limitations.
- RELAX-AHF-2Independent statistical analysis of Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- REMAINIndependent statistical analysis of A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After…
- REMDACTAIndependent statistical analysis of the REMDACTA phase 3 trial of remdesivir plus tocilizumab versus remdesivir plus placebo in hospitalized participants with severe COVID-19 pneumonia, including time-to-event, logistic regression, and categorical endpoint results.
- RESPIRE 1Independent statistical analysis of Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- REVERCEIndependent statistical analysis of the REVERCE phase 2 trial evaluating regorafenib with cetuximab or panitumumab-based treatment in colorectal cancer, including trial design, time-to-event endpoints, log-rank methodology, reported P-values, safety, and statistical interpretation.
- ROCKETIndependent statistical analysis of A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- RSVHRIndependent statistical analysis of A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- RTOG 0424Independent statistical analysis of RTOG 0424, evaluating temozolomide and radiation therapy in patients with gliomas, including trial design, time-to-event endpoints, hazard ratios, statistical methods, and interpretation.
- RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…
- RTOG 0825Independent statistical analysis of RTOG 0825, a randomized phase 3 trial of temozolomide and radiation therapy with or without bevacizumab in patients with newly diagnosed glioblastoma.
- SANDPIPERIndependent statistical analysis of A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase…
- SEAMLESSIndependent statistical analysis of A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- SERAPHINIndependent statistical analysis of SERAPHIN, the randomized phase 3 trial of macitentan in symptomatic pulmonary arterial hypertension, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, and interpretation.
- SERENA-2Independent statistical analysis of A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative…
- SHARPIndependent statistical analysis of SHARP, the randomized phase 3 study of sorafenib versus placebo in patients with advanced hepatocellular carcinoma, including its overall survival and symptomatic progression endpoints, stratified log-rank methodology, interim…
- SICOG 0109Independent statistical analysis of Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SISTErIndependent statistical analysis of Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00064662).
- SKYSCRAPER-06Independent statistical analysis of SKYSCRAPER-06, evaluating tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy in previously untreated advanced non-squamous NSCLC, with detailed interpretation of PFS, OS, response, quality-of-life, and safety analyses.
- SMA-TBIndependent statistical analysis of Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04575519).
- SOFTIndependent statistical analysis of the SOFT phase 3 trial of tamoxifen, tamoxifen plus ovarian function suppression, and exemestane plus ovarian function suppression in premenopausal women with hormone-responsive breast cancer.
- SOLO3Independent statistical analysis of the SOLO3 phase 3 trial of olaparib versus single-agent chemotherapy in relapsed germline BRCA-mutated ovarian cancer, including trial design, objective response, survival endpoints, statistical methods, safety, and interpretation.
- SOLO3Independent statistical analysis of Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received…
- SPARTANIndependent statistical analysis of the phase 3 SPARTAN trial of apalutamide versus placebo in men with non-metastatic castration-resistant prostate cancer, including metastasis-free survival, time to metastasis, progression-free survival, statistical methodology, safety, and…
- SPIRE-1An independent statistical analysis of SPIRE-1 (NCT01975376), the terminated phase 3 placebo-controlled trial of bococizumab for prevention of major cardiovascular events: stratified Cox hazard ratios, MMRM and ANCOVA lipid analyses, multiplicity and…
- SPIRE-2Independent statistical analysis of SPIRE-2 (NCT01975389), the terminated phase 3 placebo-controlled trial of bococizumab in high-risk participants: stratified Cox hazard ratios for major cardiovascular events, MMRM and ANCOVA lipid analyses, and serious…
- SPIRITIndependent statistical analysis of Antiarrhythmic Effects of Spironolactone in Patients With ICDs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04495712).
- STEP-IPFIndependent statistical analysis of STEP-IPF (NCT00517933), a randomized phase 3 trial of sildenafil versus placebo in patients with pulmonary fibrosis and pulmonary hypertension, including endpoint definitions, reported statistical analyses, interpretation, and limitations.
- SUN1058Independent statistical analysis of A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone: primary endpoint results, effect estimate with confidence interval,…
- TASCIndependent statistical analysis of Aortoiliac Stenosis in Kidney Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06020534).
- TAX316Complete statistical analysis of TAX316, a randomized phase 3 trial comparing docetaxel-containing TAC with FAC in node-positive adjuvant breast cancer, including disease-free survival, overall survival, statistical methodology, safety, and interpretation.
- TEAMIndependent statistical analysis of TEAM, the randomized phase 3 trial comparing exemestane with tamoxifen followed by exemestane in postmenopausal patients with receptor-positive breast cancer. Includes disease-free survival, overall survival, time to relapse,…
- TERIKIDSIndependent statistical analysis of Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TEXTIndependent statistical analysis of TEXT, a randomized phase 3 trial of triptorelin with either exemestane or tamoxifen in premenopausal women with hormone-responsive breast cancer, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank…
- THORIndependent statistical analysis of A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations: primary endpoint…
- TIVO-1Independent statistical analysis of A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- TNBCIndependent statistical analysis of Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TOPAZ-1Independent statistical analysis of Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- TRAILIndependent statistical analysis of Letrozole for Lymphangioleiomyomatosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01353209).